Contact
searchSearch
HMP Global
Login

News

News
Daraxonrasib Shows Clinical Promise in Patients With RAS-mutated Pancreatic Ductal Adenocarcinoma
05/07/2026
Stephanie Holland
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study...
05/07/2026
Oncology
News
First-Line Daraxonrasib Plus Gemcitabine and Nab-Paclitaxel Shows Promisie in RAS-Mutated Metastatic Pancreatic Cancer
04/24/2026
Emily Estrada
Results from a phase 1/2 study demonstrate that first-line daraxonrasib plus gemcitabine and nab-paclitaxel shows strong preliminary efficacy and safety in RAS-mutated metastatic pancreatic cancer.
Results from a phase 1/2 study demonstrate that first-line daraxonrasib plus gemcitabine and nab-paclitaxel shows strong preliminary efficacy and safety in RAS-mutated metastatic pancreatic cancer.
Results from a phase 1/2 study...
04/24/2026
Oncology
News
First-Line Daraxonrasib Shows Early Activity in RAS-Mutated Metastatic Pancreatic Cancer
04/23/2026
Stephanie Holland
Results from a phase 1/2 study demonstrate that first-line daraxonrasib shows encouraging clinical efficacy and safety in RAS-mutated metastatic pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study demonstrate that first-line daraxonrasib shows encouraging clinical efficacy and safety in RAS-mutated metastatic pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study...
04/23/2026
Oncology
News
TTFields Plus Atezolizumab and Chemotherapy Improves Disease Control in Metastatic Pancreatic Cancer
03/26/2026
Stephanie Holland
Results from the phase 2 PANOVA-4 trial demonstrated that first-line treatment with TTFields plus atezolizumab and chemotherapy achieved a higher disease control rate compared with historical control among patients with metastatic pancreatic...
Results from the phase 2 PANOVA-4 trial demonstrated that first-line treatment with TTFields plus atezolizumab and chemotherapy achieved a higher disease control rate compared with historical control among patients with metastatic pancreatic...
Results from the phase 2...
03/26/2026
Oncology
News
Durvalumab Plus Olaparib Demonstrates Strong Clinical Promise for Metastatic Pancreatic Cancer
01/12/2026
Stephanie Holland
Results from a phase 2 study show that durvalumab plus olaparib therapy demonstrates strong clinical promise among patients with DNA damage repair-altered metastatic pancreatic cancer.
Results from a phase 2 study show that durvalumab plus olaparib therapy demonstrates strong clinical promise among patients with DNA damage repair-altered metastatic pancreatic cancer.
Results from a phase 2 study...
01/12/2026
Oncology
News
Durvalumab Plus Olaparib Demonstrates Strong Clinical Promise for Metastatic Pancreatic Cancer
01/12/2026
Stephanie Holland
Results from a phase 2 study show that durvalumab plus olaparib therapy demonstrates strong clinical promise among patients with DNA damage repair-altered metastatic pancreatic cancer.
Results from a phase 2 study show that durvalumab plus olaparib therapy demonstrates strong clinical promise among patients with DNA damage repair-altered metastatic pancreatic cancer.
Results from a phase 2 study...
01/12/2026
Oncology
News
Eryaspase Demonstrates No Survival Benefit for Patients With Advanced PDAC: Phase 3 TRYBECA-1 Trial
11/20/2025
Emily Estrada
The addition of eryaspase to standard chemotherapy did not improve survival outcomes for patients with advanced pancreatic ductal adenocarcinoma, according to results from the phase 3 TRYBECA-1 trial.
The addition of eryaspase to standard chemotherapy did not improve survival outcomes for patients with advanced pancreatic ductal adenocarcinoma, according to results from the phase 3 TRYBECA-1 trial.
The addition of eryaspase to...
11/20/2025
Oncology
News
Microwave Ablation Plus Dual Checkpoint Inhibition Enhances Immune Response in Locally Advanced Pancreatic Ductal Adenocarcinoma
11/19/2025
Stephanie Holland
Combining dual durvalumab and tremelimumab with microwave tumor ablation and chemotherapy demonstrated encouraging progression-free survival and potential immune modulation among patients with unresectable, non-metastatic, locally advanced...
Combining dual durvalumab and tremelimumab with microwave tumor ablation and chemotherapy demonstrated encouraging progression-free survival and potential immune modulation among patients with unresectable, non-metastatic, locally advanced...
Combining dual durvalumab and...
11/19/2025
Oncology
News
Extending Pre-Operative Chemotherapy May Be Preferable for Resectable and Borderline Resectable Pancreatic Cancer
10/23/2025
Stephanie Holland
Results from the phase 3 CASSANDRA trial demonstrate that extending pre-operative chemotherapy may be preferable to short-course chemotherapy for resectable or borderline resectable pancreatic ductal adenocarcinoma.
Results from the phase 3 CASSANDRA trial demonstrate that extending pre-operative chemotherapy may be preferable to short-course chemotherapy for resectable or borderline resectable pancreatic ductal adenocarcinoma.
Results from the phase 3...
10/23/2025
Oncology
News
PANOVA-3 Post-Hoc Analyses Highlight Predictors of Benefit With TTFields Therapy in Pancreatic Adenocarcinoma
10/19/2025
Janelle Bradley
Higher device adherence and reductions in CA 19-9 levels may serve as early indicators of improved survival in patients with unresectable locally advanced pancreatic adenocarcinoma treated with TTFields plus gemcitabine and nab-paclitaxel,...
Higher device adherence and reductions in CA 19-9 levels may serve as early indicators of improved survival in patients with unresectable locally advanced pancreatic adenocarcinoma treated with TTFields plus gemcitabine and nab-paclitaxel,...
Higher device adherence and...
10/19/2025
Oncology

Recent News

News
Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma
06/26/2026
Emily Estrada
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an...
06/26/2026
Oncology
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients...
06/25/2026
Oncology
News
Pirtobrutinib Demonstrates Durable Clinical Activity in Relapsed or Refractory Waldenström Macroglobulinemia
06/25/2026
Stephanie Holland
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN...
06/25/2026
Oncology
News
Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma
06/25/2026
Stephanie Holland
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the...
06/25/2026
Oncology
News
Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer
06/23/2026
Emily Estrada
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study...
06/23/2026
Oncology
News
Bulumtatug Fuvedotin Demonstrates Durable Activity in Previously Treated Cervical Cancer
06/23/2026
Emily Estrada
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2...
06/23/2026
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Patients With Unresectable or Metastatic Synovial Sarcoma
06/23/2026
Stephanie Holland
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the...
06/23/2026
Oncology
News
Signatera-Based ctDNA Testing Incorporated Into NCCN Bladder Cancer Guidelines
06/23/2026
Stephanie Holland
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its...
06/23/2026
Oncology
News
Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1...
06/18/2026
Oncology
News
Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3...
06/18/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use